A citation-based method for searching scientific literature

Vit Vsiansky, Jaromir Gumulec, Martina Raudenska, Michal Masarik. Sci Rep 2018
Times Cited: 13







List of co-cited articles
88 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


HGF and c-Met participate in paracrine tumorigenic pathways in head and neck squamous cell cancer.
Lynn M Knowles, Laura P Stabile, Ann Marie Egloff, Mary E Rothstein, Sufi M Thomas, Christopher T Gubish, Edwina C Lerner, Raja R Seethala, Shinsuke Suzuki, Kelly M Quesnelle,[...]. Clin Cancer Res 2009
160
38

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
Freddie Bray, Jacques Ferlay, Isabelle Soerjomataram, Rebecca L Siegel, Lindsey A Torre, Ahmedin Jemal. CA Cancer J Clin 2018
38


Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1.
Nishant Agrawal, Mitchell J Frederick, Curtis R Pickering, Chetan Bettegowda, Kyle Chang, Ryan J Li, Carole Fakhry, Tong-Xin Xie, Jiexin Zhang, Jing Wang,[...]. Science 2011
30

Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck.
Robert L Ferris, George Blumenschein, Jerome Fayette, Joel Guigay, A Dimitrios Colevas, Lisa Licitra, Kevin Harrington, Stefan Kasper, Everett E Vokes, Caroline Even,[...]. N Engl J Med 2016
30

Platinum-based chemotherapy plus cetuximab in head and neck cancer.
Jan B Vermorken, Ricard Mesia, Fernando Rivera, Eva Remenar, Andrzej Kawecki, Sylvie Rottey, Jozsef Erfan, Dmytro Zabolotnyy, Heinz-Roland Kienzer, Didier Cupissol,[...]. N Engl J Med 2008
30

Function of the c-Met receptor tyrosine kinase in carcinogenesis and associated therapeutic opportunities.
Yazhuo Zhang, Mengfang Xia, Ke Jin, Shufei Wang, Hang Wei, Chunmei Fan, Yingfen Wu, Xiaoling Li, Xiayu Li, Guiyuan Li,[...]. Mol Cancer 2018
241
30

An overview of the c-MET signaling pathway.
Shawna Leslie Organ, Ming-Sound Tsao. Ther Adv Med Oncol 2011
472
30

The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma.
Tanguy Y Seiwert, Ramasamy Jagadeeswaran, Leonardo Faoro, Varalakshmi Janamanchi, Vidya Nallasura, Mohamed El Dinali, Soheil Yala, Rajani Kanteti, Ezra E W Cohen, Mark W Lingen,[...]. Cancer Res 2009
194
30

Prospective identification of tumorigenic breast cancer cells.
Muhammad Al-Hajj, Max S Wicha, Adalberto Benito-Hernandez, Sean J Morrison, Michael F Clarke. Proc Natl Acad Sci U S A 2003
23

Somatic mutations lead to an oncogenic deletion of met in lung cancer.
Monica Kong-Beltran, Somasekar Seshagiri, Jiping Zha, Wenjing Zhu, Kaumudi Bhawe, Nerissa Mendoza, Thomas Holcomb, Kanan Pujara, Jeremy Stinson, Ling Fu,[...]. Cancer Res 2006
352
23

The mutational landscape of head and neck squamous cell carcinoma.
Nicolas Stransky, Ann Marie Egloff, Aaron D Tward, Aleksandar D Kostic, Kristian Cibulskis, Andrey Sivachenko, Gregory V Kryukov, Michael S Lawrence, Carrie Sougnez, Aaron McKenna,[...]. Science 2011
23

Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors.
Garrett M Frampton, Siraj M Ali, Mark Rosenzweig, Juliann Chmielecki, Xinyuan Lu, Todd M Bauer, Mikhail Akimov, Jose A Bufill, Carrie Lee, David Jentz,[...]. Cancer Discov 2015
473
23

Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product.
D P Bottaro, J S Rubin, D L Faletto, A M Chan, T E Kmiecik, G F Vande Woude, S A Aaronson. Science 1991
23

Prognostic value of c-MET in head and neck cancer: A systematic review and meta-analysis of aggregate data.
Petr Szturz, Marie Budíková, Jan B Vermorken, Ivana Horová, Břetislav Gál, Eric Raymond, Armand de Gramont, Sandrine Faivre. Oral Oncol 2017
19
23


HGF and c-MET as potential orchestrators of invasive growth in head and neck squamous cell carcinoma.
Maria-Jantine De Herdt, Robert J Baatenburg de Jong. Front Biosci 2008
41
23


The molecular biology of head and neck cancer.
C René Leemans, Boudewijn J M Braakhuis, Ruud H Brakenhoff. Nat Rev Cancer 2011
23


Targeting Notch to target cancer stem cells.
Antonio Pannuti, Kimberly Foreman, Paola Rizzo, Clodia Osipo, Todd Golde, Barbara Osborne, Lucio Miele. Clin Cancer Res 2010
333
15

NOTCH1 inhibition enhances the efficacy of conventional chemotherapeutic agents by targeting head neck cancer stem cell.
Zhi-Li Zhao, Lu Zhang, Cong-Fa Huang, Si-Rui Ma, Lin-Lin Bu, Jian-Feng Liu, Guang-Tao Yu, Bing Liu, J Silvio Gutkind, Ashok B Kulkarni,[...]. Sci Rep 2016
65
15

Significance of CD44 expression in head and neck cancer: a systemic review and meta-analysis.
Jianqiang Chen, Jianding Zhou, Jie Lu, Hua Xiong, Xueli Shi, Liang Gong. BMC Cancer 2014
101
15

CD24+ tumor-initiating cells from oral squamous cell carcinoma induce initial angiogenesis in vivo.
Rüdiger M Zimmerer, Nils Ludwig, Andreas Kampmann, Gido Bittermann, Simon Spalthoff, Michael Jungheim, Nils-Claudius Gellrich, Frank Tavassol. Microvasc Res 2017
16
15

Activation of sonic hedgehog signaling in oral squamous cell carcinomas: a preliminary study.
Marcilei Eliza Cavicchioli Buim, Clarissa Araújo S Gurgel, Eduardo Antônio Gonçalves Ramos, Silvia Vanessa Lourenço, Fernando Augusto Soares. Hum Pathol 2011
26
15

Integrative genomic characterization of oral squamous cell carcinoma identifies frequent somatic drivers.
Curtis R Pickering, Jiexin Zhang, Suk Young Yoo, Linnea Bengtsson, Shhyam Moorthy, David M Neskey, Mei Zhao, Marcus V Ortega Alves, Kyle Chang, Jennifer Drummond,[...]. Cancer Discov 2013
366
15

Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy.
Jan B Vermorken, José Trigo, Ricardo Hitt, Piotr Koralewski, Eduardo Diaz-Rubio, Frédéric Rolland, Rainald Knecht, Nadia Amellal, Armin Schueler, José Baselga. J Clin Oncol 2007
699
15

Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping.
Paul K Paik, Alexander Drilon, Pang-Dian Fan, Helena Yu, Natasha Rekhtman, Michelle S Ginsberg, Laetitia Borsu, Nikolaus Schultz, Michael F Berger, Charles M Rudin,[...]. Cancer Discov 2015
412
15

TP53 mutations and survival in squamous-cell carcinoma of the head and neck.
M Luana Poeta, Judith Manola, Meredith A Goldwasser, Arlene Forastiere, Nicole Benoit, Joseph A Califano, John A Ridge, Jarrard Goodwin, Daniel Kenady, John Saunders,[...]. N Engl J Med 2007
513
15

Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study.
Ezra E W Cohen, Denis Soulières, Christophe Le Tourneau, José Dinis, Lisa Licitra, Myung-Ju Ahn, Ainara Soria, Jean-Pascal Machiels, Nicolas Mach, Ranee Mehra,[...]. Lancet 2019
740
15

Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting.
John C Sok, Francesca M Coppelli, Sufi M Thomas, Miriam N Lango, Sichuan Xi, Jennifer L Hunt, Maria L Freilino, Michael W Graner, Carol J Wikstrand, Darell D Bigner,[...]. Clin Cancer Res 2006
360
15

Mutation of the c-Cbl TKB domain binding site on the Met receptor tyrosine kinase converts it into a transforming protein.
P Peschard, T M Fournier, L Lamorte, M A Naujokas, H Band, W Y Langdon, M Park. Mol Cell 2001
324
15

Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification.
Sai-Hong Ignatius Ou, Eunice L Kwak, Christina Siwak-Tapp, Joni Dy, Kristin Bergethon, Jeffrey W Clark, D Ross Camidge, Benjamin J Solomon, Robert G Maki, Yung-Jue Bang,[...]. J Thorac Oncol 2011
339
15

Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas.
L Schmidt, F M Duh, F Chen, T Kishida, G Glenn, P Choyke, S W Scherer, Z Zhuang, I Lubensky, M Dean,[...]. Nat Genet 1997
15

Interplay between scatter factor receptors and B plexins controls invasive growth.
Paolo Conrotto, Simona Corso, Sara Gamberini, Paolo Maria Comoglio, Silvia Giordano. Oncogene 2004
143
15

Co-expression and prognostic significance of the HER family members, EGFRvIII, c-MET, CD44 in patients with ovarian cancer.
Soozana Puvanenthiran, Sharadah Essapen, Ben Haagsma, Izhar Bagwan, Margaret Green, Said Abdullah Khelwatty, Alan Seddon, Helmout Modjtahedi. Oncotarget 2018
8
25

Predictive role of the overexpression for CXCR4, C-Met, and VEGF-C among breast cancer patients: A meta-analysis.
Fang Wang, Shanshan Li, Yueguang Zhao, Kunxian Yang, Minju Chen, Heng Niu, Jingyu Yang, Ying Luo, Wenru Tang, Miaomiao Sheng. Breast 2016
21
15

Prognostic implication of serum hepatocyte growth factor in stage II/III breast cancer patients who received neoadjuvant chemotherapy.
Hyori Kim, Jeonghwan Youk, Yaewon Yang, Tae-Yong Kim, Ahrum Min, Hye-Seon Ham, Seongcheol Cho, Kyung-Hun Lee, Bhumsuk Keam, Sae-Won Han,[...]. J Cancer Res Clin Oncol 2016
7
28

Prognostic or predictive value of circulating cytokines and angiogenic factors for initial treatment of multiple myeloma in the GIMEMA MM0305 randomized controlled trial.
Ilaria Saltarella, Fortunato Morabito, Nicola Giuliani, Carolina Terragna, Paola Omedè, Antonio Palumbo, Sara Bringhen, Lorenzo De Paoli, Enrica Martino, Alessandra Larocca,[...]. J Hematol Oncol 2019
18
15

Expression and mutational analysis of MET in human solid cancers.
Patrick C Ma, Maria S Tretiakova, Alexander C MacKinnon, Nithya Ramnath, Candace Johnson, Sascha Dietrich, Tanguy Seiwert, James G Christensen, Ramasamy Jagadeeswaran, Thomas Krausz,[...]. Genes Chromosomes Cancer 2008
239
15

MET tyrosine kinase receptor expression and amplification as prognostic biomarkers of survival in gastroesophageal adenocarcinoma.
Daniel V T Catenacci, Agnes Ang, Wei-Li Liao, Jing Shen, Emily O'Day, Robert D Loberg, Fabiola Cecchi, Todd Hembrough, Annamaria Ruzzo, Francesco Graziano. Cancer 2017
24
15

Diagnosis and Prognostic Significance of c-Met in Cervical Cancer: A Meta-Analysis.
Jifeng Peng, Shengnan Qi, Ping Wang, Wanyu Li, Chunxia Liu, Feng Li. Dis Markers 2016
25
15


Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors.
D Westover, J Zugazagoitia, B C Cho, C M Lovly, L Paz-Ares. Ann Oncol 2018
265
15


Evaluation of Intratumoral and Intertumoral Heterogeneity of MET Protein Expression in Gastric Cancer.
Jiwoon Choi, Hee Eun Lee, Hye Seung Lee, Nayoung Han, Min A Kim, Woo Ho Kim. Appl Immunohistochem Mol Morphol 2018
7
28

Correlation between HGF/c-Met and Notch1 signaling pathways in human gastric cancer cells.
Kuo-Hung Huang, I-Cheng Sung, Wen-Liang Fang, Chin-Wen Chi, Tien-Shun Yeh, Hsin-Chen Lee, Pen-Hui Yin, Anna Fen-Yau Li, Chew-Wun Wu, Yi-Ming Shyr,[...]. Oncol Rep 2018
14
15

Clinicopathological implications of MET exon 14 mutations in non-small cell lung cancer - A systematic review and meta-analysis.
Huy Gia Vuong, An Thi Nhat Ho, Ahmed M A Altibi, Tadao Nakazawa, Ryohei Katoh, Tetsuo Kondo. Lung Cancer 2018
61
15

Prognostic significance of targetable angiogenic and growth factors in patients undergoing resection for gastric and gastroesophageal junction cancers.
Do Joong Park, Changhwan Yoon, Nicholas Thomas, Geoffrey Y Ku, Yelena Y Janjigian, David P Kelsen, David H Ilson, Karyn A Goodman, Laura H Tang, Vivian E Strong,[...]. Ann Surg Oncol 2014
19
15

Serum concentrations of HGF are correlated with response to anti-PD-1 antibody therapy in patients with metastatic melanoma.
Yosuke Kubo, Satoshi Fukushima, Yukiko Inamori, Mina Tsuruta, Sho Egashira, Saori Yamada-Kanazawa, Satoshi Nakahara, Aki Tokuzumi, Azusa Miyashita, Jun Aoi,[...]. J Dermatol Sci 2019
12
16


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.